Medical Pharmacology: Chapter: 26 — Renal Pharmacology -- Module: 5 — Fluid, Acid-Base, and Electrolyte Emergencies

Chapter: 26 — Renal Pharmacology — Module: 5 — Fluid, Acid-Base, and Electrolyte Emergencies
Tier: CC (Confidence Check)

1. A 68-year-old man with end-stage renal disease presents with weakness and palpitations. Serum potassium is 7.2 mEq/L. The ECG shows peaked T waves, widened QRS (ventricular depolarization complex) complexes, and a PR interval of 240 ms. Calcium gluconate 1 g IV is administered over 10 minutes. Which of the following most accurately describes the mechanism by which calcium gluconate reduces the immediate risk of ventricular fibrillation in this patient?

A) It activates Na/K-ATPase in skeletal muscle, shifting potassium from the extracellular to intracellular compartment
B) It raises the threshold potential of cardiac myocytes, increasing the gap between the resting membrane potential and the action potential threshold, thereby reducing myocardial excitability
C) It binds potassium directly in the gastrointestinal tract, reducing total body potassium load within 30 minutes
D) It stimulates beta-2 adrenergic receptors on cardiac muscle, activating cAMP-mediated potassium uptake
E) It alkalinizes the plasma, driving potassium into cells in exchange for hydrogen ions

ANSWER: B

Rationale:

Calcium gluconate acts by raising the threshold potential of cardiac myocytes — the voltage that must be reached to trigger an action potential. In hyperkalemia, the resting membrane potential is less negative (depolarized) due to the reduced electrochemical gradient for potassium efflux, bringing the resting potential dangerously close to the action potential threshold and creating electrical instability. Calcium ions increase the threshold potential, restoring the gap between resting and threshold potentials and reducing spontaneous excitability and arrhythmia risk. This action has an onset of 1–3 minutes and duration of 30–60 minutes. Crucially, calcium gluconate does not lower serum potassium, does not shift potassium into cells, and does not remove potassium from the body; it is solely a cardiac membrane stabilizer, and definitive potassium removal must always follow.

Option A: Option A is incorrect: Na/K-ATPase activation by insulin, not calcium, mediates potassium redistribution into skeletal muscle cells.
Option C: Option C is incorrect: gastrointestinal cation exchange is the mechanism of patiromer and sodium zirconium cyclosilicate, not calcium gluconate, and neither acts within 30 minutes for acute emergencies.
Option D: Option D is incorrect: beta-2 adrenergic stimulation is the mechanism by which high-dose nebulized albuterol lowers potassium; calcium gluconate has no beta-adrenergic activity.
Option E: Option E is incorrect: plasma alkalinization driving potassium into cells in exchange for hydrogen ions describes a component of the bicarbonate mechanism in severe acidemia, not calcium gluconate's action.

2. A 72-year-old woman with CKD stage 5 presents with serum potassium of 6.8 mEq/L and peaked T waves on ECG. After calcium gluconate is administered, the team proceeds to the redistribution phase of treatment. Regular insulin 10 units IV is given with 50 mL of 50% dextrose. Which of the following best describes the mechanism by which this intervention lowers serum potassium?

A) Insulin activates adenylate cyclase in collecting duct principal cells, stimulating AQP2-mediated fluid shifts that dilute extracellular potassium
B) Insulin binds to alpha-1 adrenergic receptors on hepatocytes, triggering glycogen synthesis and intracellular sequestration of potassium
C) Insulin stimulates renal potassium excretion by upregulating ROMK channel expression in the thick ascending limb
D) Insulin stimulates Na/K-ATPase activity in skeletal muscle cells, driving potassium from the extracellular fluid into the intracellular compartment
E) Insulin alkalinizes tubular fluid by inhibiting carbonic anhydrase, increasing electronegativity in the collecting duct lumen and drawing potassium into urine

ANSWER: D

Rationale:

Insulin stimulates Na/K-ATPase (sodium-potassium ATPase) in skeletal muscle cells, the enzyme that pumps 3 sodium ions out of the cell in exchange for 2 potassium ions into the cell per ATP cycle. This increased pump activity drives potassium from the extracellular fluid into the intracellular compartment, lowering serum potassium by approximately 0.5–1.5 mEq/L over 15–30 minutes. Dextrose is co-administered to prevent hypoglycemia; in hyperglycemic patients (glucose above 250 mg/dL), dextrose can be withheld. This redistribution effect is temporary — lasting 4–6 hours — and does not remove potassium from the body; definitive elimination via diuretics, cation exchangers, or dialysis must follow.

Option A: Option A is incorrect: adenylate cyclase activation and AQP2 insertion are the mechanisms of vasopressin (ADH) in collecting duct water reabsorption, not the mechanism of insulin in potassium regulation.
Option B: Option B is incorrect: insulin acts on insulin receptors (tyrosine kinase-linked), not alpha-1 adrenergic receptors; insulin promotes glycogen synthesis but the potassium-lowering effect is via Na/K-ATPase, not glycogen sequestration.
Option C: Option C is incorrect: insulin does not upregulate ROMK (renal outer medullary potassium channel) expression; ROMK mediates potassium secretion in the collecting duct and is regulated by aldosterone, not insulin.
Option E: Option E is incorrect: carbonic anhydrase inhibition is the mechanism of acetazolamide; insulin has no direct effect on tubular carbonic anhydrase or urinary potassium handling.

3. A hospitalized patient with CKD stage 4 and chronic hyperkalemia (serum K 5.9 mEq/L) requires an oral potassium binder for outpatient management after discharge. The team is choosing between patiromer and sodium zirconium cyclosilicate (SZC). Which of the following statements most accurately distinguishes these two agents?

A) SZC has an onset of approximately 1 hour and regulatory approval for both acute and chronic hyperkalemia management, whereas patiromer has a slower onset of 4–24 hours and is approved for chronic management only
B) Patiromer is a potassium-zirconium crystal that binds potassium throughout the gastrointestinal tract, whereas SZC is a calcium-zirconium polymer that binds potassium only in the colon
C) Both agents are appropriate for acute emergency management of hyperkalemia in the ED setting and have equivalent onset profiles when given orally
D) Patiromer exchanges sodium for potassium in the gastrointestinal tract, making it the preferred agent in patients with hypertension or heart failure where sodium loading is a concern
E) SZC requires refrigeration and has a significantly higher risk of constipation compared with patiromer due to its calcium-exchange mechanism

ANSWER: A

Rationale:

SZC (sodium zirconium cyclosilicate; Lokelma) is a highly selective potassium-zirconium crystal that traps potassium throughout the gastrointestinal tract via ion exchange, with an onset of approximately 1 hour and regulatory approval for both acute and chronic hyperkalemia management. Patiromer (Veltassa) is a non-absorbed calcium-zirconium polymer that binds potassium in the colon in exchange for calcium; its onset is 4–24 hours, which is too slow for acute emergencies, and it is approved for chronic hyperkalemia management. For a patient being discharged on chronic therapy, either agent is pharmacologically appropriate; however, understanding the onset distinction is clinically critical when the same question arises in the acute inpatient setting.

Option B: Option B is incorrect: the descriptions are reversed — SZC is the potassium-zirconium crystal acting throughout the GI tract, while patiromer is the calcium-zirconium polymer acting in the colon.
Option C: Option C is incorrect: patiromer's onset of 4–24 hours makes it inappropriate for acute emergency management; only SZC has regulatory approval for acute use.
Option D: Option D is incorrect: patiromer exchanges calcium (not sodium) for potassium; SZC exchanges sodium and hydrogen for potassium, which is the agent with a sodium component to consider.
Option E: Option E is incorrect: SZC does not require refrigeration; the description conflates storage and side effect profiles not supported by the comparative pharmacology described in the content.

4. A 55-year-old woman with small cell lung cancer presents with nausea, confusion, and serum sodium of 118 mEq/L. She is euvolemic on examination. Urine sodium is 45 mEq/L and urine osmolality is 520 mOsm/kg. The diagnosis of SIADH (syndrome of inappropriate antidiuretic hormone secretion) is made. The team considers initiating 0.9% normal saline. Which of the following best explains why isotonic saline is contraindicated as a treatment for this patient's hyponatremia?

A) Isotonic saline will cause a rapid rise in serum sodium exceeding 12 mEq/L in 24 hours, causing osmotic demyelination syndrome in all SIADH patients
B) Isotonic saline provides free water that dilutes the serum sodium further, worsening hyponatremia in all hospitalized patients regardless of volume status
C) In SIADH, the kidneys retain free water under persistent ADH stimulation; the sodium in infused isotonic saline is excreted in concentrated urine while the water is retained, paradoxically worsening hyponatremia
D) Isotonic saline is contraindicated in SIADH because its osmolality exceeds the maximum urine concentrating ability of SIADH-affected kidneys, causing obligate free water excretion and worsening volume depletion
E) Isotonic saline activates the renin-angiotensin system, increasing ADH release and worsening antidiuresis in SIADH patients

ANSWER: C

Rationale:

In SIADH, ADH continues to act on collecting duct V2 receptors regardless of osmolality, driving maximal water reabsorption. When isotonic saline is infused, the sodium it contains is excreted in highly concentrated urine (urine osmolality often exceeding 500 mOsm/kg as in this patient), but the water from the infusion is retained under the ongoing ADH effect. The net result is water retention without proportional sodium retention, paradoxically lowering serum sodium further. This is the fundamental reason isotonic saline is contraindicated in SIADH. The correct treatments are fluid restriction, hypertonic saline for symptomatic cases, or pharmacological aquaresis with vaptans or urea.

Option A: Option A is incorrect: while overcorrection causing ODS is a real risk, saline is not contraindicated because it invariably causes overcorrection — it is contraindicated because it worsens hyponatremia, not because it corrects it too rapidly.
Option B: Option B is incorrect: isotonic saline does not provide free water in the strict sense (it is isotonic, not hypotonic), but the paradoxical worsening in SIADH occurs through the specific mechanism of concentrated urinary sodium excretion with retained water, not simple free water dilution.
Option D: Option D is incorrect: the reasoning is pharmacologically inverted — in SIADH the urine is already concentrated by excess ADH; the issue is that sodium excretion in concentrated urine leaves retained water behind.
Option E: Option E is incorrect: isotonic saline does not activate the RAAS in a way that increases ADH release in SIADH; ADH hypersecretion in SIADH is autonomous (non-osmotic, non-hemodynamic), not driven by RAAS activation from saline infusion.

5. A 62-year-old man with alcoholic liver disease and chronic malnutrition is admitted with serum sodium of 110 mEq/L. He has been hyponatremic for at least 5 days. Hypertonic 3% saline is initiated. Six hours into treatment, repeat sodium is 121 mEq/L — an 11 mEq/L rise. Which of the following best describes the immediate management priority and the underlying reason for it?

A) Continue the current infusion rate because a rise of 11 mEq/L in 6 hours is within the safe 24-hour limit of 12 mEq/L and no intervention is needed until the 24-hour sodium measurement is obtained
B) Administer furosemide IV to increase free water excretion and accelerate sodium normalization, as reaching 130 mEq/L within 24 hours is the target in symptomatic chronic hyponatremia
C) Switch from 3% saline to isotonic saline at the same infusion rate; this slows the correction to a safe pace while continuing to raise sodium toward the target range
D) Administer desmopressin intranasally to clampen free water excretion, then re-check sodium in 4 hours before deciding whether to stop the hypertonic saline infusion
E) Stop the hypertonic saline immediately; the 11 mEq/L rise in 6 hours far exceeds the safe correction limit of 6–8 mEq/L per 24 hours; administer desmopressin and free water to actively re-lower serum sodium, as this patient's risk profile — severe baseline hyponatremia, chronic duration, alcoholism, malnutrition, and liver disease — places him at the highest risk for osmotic demyelination syndrome

ANSWER: E

Rationale:

The safe correction limit for chronic hyponatremia is 6–8 mEq/L in the first 24 hours (absolute maximum 10–12 mEq/L in any 24-hour period). This patient's sodium has already risen 11 mEq/L in just 6 hours — at this rate, the 24-hour rise would approach 40 mEq/L, which is catastrophic. This patient carries multiple high-risk features for osmotic demyelination syndrome (ODS): serum sodium below 115 mEq/L at baseline, chronic hyponatremia for at least 5 days (allowing full cerebral adaptation), alcoholism, malnutrition, and liver disease. The immediate action is to stop the hypertonic saline, administer desmopressin (DDAVP) to reduce further free water excretion and halt additional sodium rise, and give free water orally or as D5W IV to actively re-lower the serum sodium back toward the safe correction zone. Allowing the correction to continue risks devastating pontine and extrapontine demyelination causing locked-in syndrome, spastic quadriparesis, and death.

Option A: Option A is incorrect: the 11 mEq/L rise occurred in only 6 hours, not 24 hours; the safe 24-hour limit has already been substantially exceeded and continuing the infusion is contraindicated.
Option B: Option B is incorrect: furosemide promotes free water excretion and would worsen overcorrection; the sodium rise must be halted and reversed, not accelerated.
Option C: Option C is incorrect: switching to isotonic saline does not reverse the overcorrection that has already occurred; the priority is active re-lowering of sodium with desmopressin and free water, not merely slowing a continuing rise.
Option D: Option D is incorrect: waiting 4 hours before stopping the hypertonic saline allows additional dangerous correction to occur; the 11 mEq/L rise already exceeds the 24-hour safety limit and the infusion must stop immediately, not after further monitoring.

6. A 45-year-old man presents with vomiting, altered mental status, and an arterial blood gas showing pH 7.22, HCO₃⁻ 10 mEq/L. The serum electrolytes are: Na 138 mEq/L, Cl 102 mEq/L, K 4.1 mEq/L. Which of the following best characterizes this patient's acid-base disorder, and what is the most likely category of etiology?

A) Non-anion gap metabolic acidosis with anion gap of 10 mEq/L, consistent with renal tubular acidosis or gastrointestinal bicarbonate loss
B) High anion gap metabolic acidosis with anion gap of 26 mEq/L, consistent with accumulation of an unmeasured anion such as lactate, ketoacids, or toxic alcohol metabolites
C) Respiratory acidosis with compensatory metabolic alkalosis, anion gap 26 mEq/L, consistent with hypoventilation-driven CO₂ retention
D) Mixed metabolic alkalosis and respiratory acidosis, anion gap 10 mEq/L, consistent with diuretic use and concurrent hypoventilation
E) Non-anion gap metabolic acidosis with anion gap of 26 mEq/L, consistent with Type 1 renal tubular acidosis and concurrent hyperchloremia

ANSWER: B

Rationale:

The anion gap (AG) is calculated as Na − (Cl + HCO₃) = 138 − (102 + 10) = 26 mEq/L. Normal AG is ≤12 mEq/L. An AG of 26 mEq/L is markedly elevated, indicating the presence of an unmeasured anion in the plasma. Combined with the low pH (7.22) and low HCO₃ (10 mEq/L), this is a high anion gap metabolic acidosis (HAGMA). The major causes of HAGMA are lactic acidosis, diabetic ketoacidosis (DKA) and other ketoacidoses, toxic ingestions (methanol, ethylene glycol, salicylates), and uremic acidosis (late CKD with unmeasured organic anion accumulation). The clinical context of vomiting and altered mental status in a 45-year-old raises particular concern for toxic ingestion or DKA.

Option A: Option A is incorrect: the AG calculation yields 26 mEq/L (138 − 102 − 10 = 26), not 10 mEq/L; this is a high anion gap disorder, not a normal anion gap disorder.
Option C: Option C is incorrect: the primary disturbance is metabolic (low HCO₃), not respiratory; respiratory acidosis presents with high CO₂ and elevated HCO₃ as compensation, the reverse of this pattern.
Option D: Option D is incorrect: there is no evidence of metabolic alkalosis (HCO₃ is markedly low at 10 mEq/L), and the anion gap calculation does not support a normal-gap disorder.
Option E: Option E is incorrect: while type 1 RTA can cause metabolic acidosis, it produces a normal anion gap (hyperchloremic) pattern, not a high anion gap of 26 mEq/L; the description is internally contradictory.

7. A 58-year-old man with CKD stage 4 (eGFR 22 mL/min/1.73m²) has a serum bicarbonate of 19 mEq/L on routine labs. He has no symptoms of RTA and no overt acid-base emergency. His nephrologist recommends starting oral sodium bicarbonate supplementation. Which of the following best justifies this decision?

A) Serum HCO₃ below 22 mEq/L in CKD indicates a level at which sodium bicarbonate supplementation is recommended because acidosis at this threshold accelerates CKD progression through mechanisms including complement activation and tubular injury
B) Oral sodium bicarbonate is indicated only when serum HCO₃ falls below 15 mEq/L in CKD, as above this level the kidneys can adequately compensate without pharmacological intervention
C) Sodium bicarbonate supplementation in CKD is recommended at any HCO₃ level to prevent cardiovascular complications, regardless of the degree of acidosis
D) The indication for sodium bicarbonate in this patient is to correct the metabolic component of his mixed acid-base disorder, which requires confirmation by arterial blood gas before initiating treatment
E) Sodium bicarbonate is contraindicated in CKD stage 4 due to the risk of sodium loading worsening hypertension and volume overload, and alkali supplementation in this range should use tromethamine (THAM) instead

ANSWER: A

Rationale:

In CKD without overt RTA, metabolic acidosis results from reduced net acid excretion as functional nephron mass declines. The current evidence-based threshold for initiating oral sodium bicarbonate supplementation is serum HCO₃ below 22 mEq/L. At this level, acidosis accelerates CKD progression through multiple mechanisms, including enhanced complement activation along the alternative pathway, increased tubular ammonia production driving interstitial inflammation, and direct tubular injury from acidic intracellular pH. The KDIGO 2024 CKD guidelines recommend maintaining serum HCO₃ at or above 22 mEq/L with oral bicarbonate supplementation. This is also the treatment threshold for type 4 RTA, the most common RTA pattern in CKD.

Option B: Option B is incorrect: the threshold is 22 mEq/L, not 15 mEq/L; waiting until HCO₃ falls to 15 mEq/L allows accelerated nephron loss during the interval of undertreated acidosis.
Option C: Option C is incorrect: there is no recommendation for universal bicarbonate supplementation at any HCO₃ level regardless of acidosis degree; the intervention is triggered by the 22 mEq/L threshold.
Option D: Option D is incorrect: the indication for bicarbonate in CKD-associated metabolic acidosis does not require arterial blood gas confirmation; venous HCO₃ below 22 mEq/L in the appropriate clinical context is sufficient to initiate treatment.
Option E: Option E is incorrect: THAM (tromethamine) is used in specific settings such as severe combined metabolic and respiratory acidosis where CO₂ generation or sodium loading are absolute contraindications; it is not the standard alkali agent for CKD-associated metabolic acidosis, and sodium bicarbonate is not categorically contraindicated in CKD stage 4.

8. A 34-year-old woman with a history of recurrent vomiting from an eating disorder presents with weakness and serum bicarbonate of 38 mEq/L, pH 7.52, potassium 2.8 mEq/L, and chloride 88 mEq/L. Urine chloride is 8 mEq/L. Which of the following best explains why urine chloride is the pivotal diagnostic test for classifying her metabolic alkalosis, and what the result indicates?

A) Urine chloride above 20 mEq/L in this patient would indicate primary hyperaldosteronism driving ongoing chloride excretion, requiring aldosterone antagonist therapy rather than saline
B) Urine chloride below 20 mEq/L, as in this patient, indicates chloride depletion and volume contraction as the driving mechanism, classifying this as chloride-responsive metabolic alkalosis that will correct with saline and potassium chloride repletion
C) Urine chloride is used to distinguish metabolic alkalosis from respiratory alkalosis, with values below 20 mEq/L confirming the metabolic rather than respiratory origin of the pH disturbance
D) Urine chloride below 20 mEq/L indicates aldosterone-driven hydrogen ion secretion in the collecting duct that is independent of volume status, requiring direct aldosterone blockade rather than saline
E) Urine chloride measurement in metabolic alkalosis distinguishes saline-responsive from bicarbonate-responsive alkalosis, with low values indicating the need for supplemental bicarbonate

ANSWER: B

Rationale:

Urine chloride is the pivotal test that classifies metabolic alkalosis into the two principal management categories. Chloride-responsive metabolic alkalosis (urine chloride below 20 mEq/L) indicates chloride and volume depletion as the driving mechanism. In this patient, chronic vomiting causes loss of hydrochloric acid (HCl) from gastric secretions, leading to chloride depletion, volume contraction, and secondary hyperaldosteronism — the kidney avidly conserves chloride, producing a low urine chloride. The alkalosis is perpetuated by: (1) chloride depletion impairing bicarbonate excretion, (2) volume contraction stimulating aldosterone, and (3) hypokalemia driving H⁺ secretion in the collecting duct to conserve potassium. Treatment is isotonic saline and potassium chloride (KCl) repletion, which corrects the chloride deficit and removes the stimulus for bicarbonate reabsorption.

Option A: Option A is incorrect: urine chloride above 20 mEq/L (chloride-resistant alkalosis) indicates ongoing aldosterone-driven pathology; this patient's urine chloride of 8 mEq/L is below 20 mEq/L, indicating the opposite — chloride depletion.
Option C: Option C is incorrect: urine chloride does not distinguish metabolic from respiratory alkalosis; arterial blood gas interpretation (PCO₂, pH, HCO₃) performs that function.
Option D: Option D is incorrect: urine chloride below 20 mEq/L indicates chloride-responsive, not chloride-resistant alkalosis; aldosterone-driven chloride-resistant alkalosis produces a high urine chloride because ongoing aldosterone maintains chloride excretion.
Option E: Option E is incorrect: the classification is chloride-responsive vs. chloride-resistant (not bicarbonate-responsive); low urine chloride indicates the need for saline and KCl, not bicarbonate supplementation.

9. Continuing with the same patient from Question 8 — a 34-year-old woman with metabolic alkalosis from recurrent vomiting, serum bicarbonate 38 mEq/L, potassium 2.8 mEq/L, and urine chloride 8 mEq/L. The team initiates treatment. Which of the following best describes the mechanism by which the correct treatment reverses the metabolic alkalosis?

A) Isotonic saline alkalinizes the tubular fluid, reducing the electrochemical gradient for bicarbonate reabsorption in the proximal convoluted tubule and forcing bicarbonate excretion
B) Potassium chloride repletion alone corrects metabolic alkalosis by restoring intracellular potassium, which inhibits aldosterone synthesis and eliminates the mineralocorticoid-driven component of the alkalosis
C) Isotonic saline and potassium chloride repletion correct the chloride deficit, restore volume, and suppress secondary hyperaldosteronism, removing the stimulus for bicarbonate reabsorption in the proximal tubule and hydrogen ion secretion in the collecting duct
D) Acetazolamide is the correct treatment in this patient because carbonic anhydrase inhibition in the PCT forces urinary bicarbonate wasting and corrects the alkalosis without sodium loading
E) Hemodialysis is required to remove excess bicarbonate because the serum HCO₃ of 38 mEq/L exceeds the renal threshold for bicarbonate reabsorption, making pharmacological correction insufficient

ANSWER: C

Rationale:

In chloride-responsive metabolic alkalosis driven by vomiting, the alkalosis is maintained by three interlocking mechanisms: (1) chloride depletion, which impairs the chloride-bicarbonate exchanger in the collecting duct, reducing bicarbonate secretion; (2) volume depletion activating the renin-angiotensin-aldosterone system (RAAS), which drives sodium reabsorption and secondary hydrogen ion secretion in the collecting duct; and (3) hypokalemia causing potassium-hydrogen exchange in the collecting duct — the cell secretes H⁺ to conserve K⁺, perpetuating the alkalosis. Isotonic saline restores volume (suppressing RAAS and secondary aldosteronism) and repletes chloride. KCl repletion corrects hypokalemia, stopping the potassium-driven H⁺ secretion. Together, these interventions remove all three maintaining stimuli and allow the kidney to excrete the excess bicarbonate.

Option A: Option A is incorrect: isotonic saline does not alkalinize tubular fluid; the mechanism is volume and chloride repletion suppressing RAAS and restoring the conditions for bicarbonate excretion.
Option B: Option B is incorrect: while KCl repletion is essential, potassium alone does not fully correct the alkalosis because the chloride deficit and volume contraction also contribute; potassium chloride is needed in combination with saline, not instead of it.
Option D: Option D is incorrect: acetazolamide is used in chloride-resistant metabolic alkalosis in volume-overloaded patients (heart failure) who cannot receive saline; this patient has chloride-responsive alkalosis from volume depletion, in whom saline is the appropriate treatment and acetazolamide would be inappropriate.
Option E: Option E is incorrect: hemodialysis is not indicated for metabolic alkalosis from vomiting; the condition is fully correctable with saline and KCl in chloride-responsive cases.

10. A 78-year-old man with CKD stage 5 and serum potassium of 6.6 mEq/L has already received calcium gluconate and insulin with dextrose. The team wishes to add a second redistributive agent to further lower potassium before dialysis. Nebulized albuterol is ordered at 20 mg (high-dose). Which of the following best describes the mechanism by which high-dose albuterol lowers serum potassium?

A) Albuterol activates alpha-1 adrenergic receptors on renal tubular cells, increasing urinary potassium excretion through ROMK channel upregulation in the collecting duct
B) Albuterol directly inhibits Na/K-ATPase in cardiac myocytes, reducing intracellular potassium efflux and stabilizing the cardiac membrane potential
C) Albuterol antagonizes vasopressin V2 receptors in the collecting duct, increasing free water excretion and diluting extracellular potassium concentration
D) Albuterol activates alpha-2 adrenergic receptors on pancreatic beta cells, stimulating insulin release, which then activates Na/K-ATPase to drive potassium into cells
E) Albuterol activates beta-2 adrenergic receptors on skeletal muscle cells, stimulating cAMP-mediated activation of Na/K-ATPase and driving potassium from the extracellular fluid into cells

ANSWER: E

Rationale:

High-dose nebulized albuterol (10–20 mg, four to eight times the standard bronchodilator dose) lowers serum potassium by activating beta-2 adrenergic receptors on skeletal muscle cells. Beta-2 receptor activation stimulates adenylate cyclase, increasing intracellular cyclic AMP (cAMP) levels, which activates Na/K-ATPase. This drives potassium from the extracellular compartment into skeletal muscle cells, lowering serum potassium by an additional 0.5–1.0 mEq/L over 30–90 minutes. The effect is additive to insulin and acts through the same final effector (Na/K-ATPase) via a distinct receptor-signaling pathway. Because this is a redistribution effect, not elimination, potassium will return to the serum when the effect wears off. Tachycardia is an expected side effect due to beta-1 receptor cross-stimulation at high doses.

Option A: Option A is incorrect: albuterol is a beta-2 agonist, not an alpha-1 agonist; it does not directly increase urinary potassium excretion via ROMK upregulation, which is regulated by aldosterone.
Option B: Option B is incorrect: albuterol does not inhibit Na/K-ATPase; it activates it indirectly through the cAMP pathway; direct Na/K-ATPase inhibition is the mechanism of cardiac glycosides such as digoxin.
Option C: Option C is incorrect: albuterol has no direct antagonist activity at vasopressin V2 receptors; aquaresis is the mechanism of vaptans (tolvaptan, conivaptan).
Option D: Option D is incorrect: albuterol activates beta-2, not alpha-2, receptors; furthermore, alpha-2 adrenergic stimulation on pancreatic beta cells inhibits (not stimulates) insulin release, which would worsen hyperkalemia.

11. A 67-year-old man with decompensated heart failure and volume overload develops serum bicarbonate of 34 mEq/L and pH 7.49. His team identifies contraction alkalosis perpetuated by aggressive loop diuretic therapy. They note that the metabolic alkalosis is impairing loop diuretic responsiveness. Acetazolamide is added to the regimen. Which of the following best describes the mechanism by which acetazolamide corrects the metabolic alkalosis in this patient?

A) Acetazolamide inhibits aldosterone binding to the mineralocorticoid receptor in the collecting duct, reducing hydrogen ion secretion and allowing bicarbonate to accumulate in the tubular lumen for excretion
B) Acetazolamide inhibits carbonic anhydrase in the proximal convoluted tubule, impairing bicarbonate reabsorption and forcing urinary bicarbonate wasting, thereby lowering serum bicarbonate without sodium loading
C) Acetazolamide blocks the Na-K-2Cl cotransporter in the thick ascending limb, preventing chloride reabsorption and restoring the chloride gradient needed for collecting duct bicarbonate secretion
D) Acetazolamide stimulates renal potassium excretion in the distal convoluted tubule, correcting the hypokalemia that perpetuates hydrogen ion secretion and thus indirectly resolving the alkalosis
E) Acetazolamide alkalinizes the urine by inhibiting tubular H⁺ secretion across the entire nephron, creating a pH gradient that passively drives bicarbonate excretion by diffusion

ANSWER: B

Rationale:

Acetazolamide inhibits carbonic anhydrase (CA) in the proximal convoluted tubule (PCT). CA is required to convert filtered bicarbonate into CO₂ and water at the luminal surface, allowing CO₂ to diffuse into the cell where it is reconverted to HCO₃⁻ for reabsorption. When CA is inhibited, this reconversion cannot occur efficiently, bicarbonate reabsorption in the PCT falls, and bicarbonate is excreted in the urine. This urinary bicarbonate wasting lowers serum bicarbonate toward normal without adding sodium, making acetazolamide the appropriate agent for volume-overloaded patients who cannot receive isotonic saline to correct contraction alkalosis. The ADVOR trial demonstrated that acetazolamide added to IV loop diuretics improved decongestion in hospitalized heart failure patients, in part through this alkalosis-correcting mechanism that restores loop diuretic efficacy.

Option A: Option A is incorrect: acetazolamide acts on carbonic anhydrase, not on the mineralocorticoid receptor; aldosterone receptor antagonism is the mechanism of spironolactone and eplerenone.
Option C: Option C is incorrect: the Na-K-2Cl cotransporter in the thick ascending limb is inhibited by loop diuretics (furosemide, bumetanide, torsemide), not by acetazolamide.
Option D: Option D is incorrect: while acetazolamide does cause some potassium wasting (as sodium and potassium are excreted with bicarbonate in the urine), its primary mechanism for correcting alkalosis is bicarbonate excretion, not potassium-mediated indirect resolution of H⁺ secretion.
Option E: Option E is incorrect: acetazolamide inhibits CA specifically in the PCT, not H⁺ secretion across the entire nephron; the collecting duct H⁺-ATPase and H/K-ATPase are not direct targets of acetazolamide.

12. A 61-year-old man with heart failure and euvolemic hyponatremia (serum Na 124 mEq/L, normal volume status on examination, urine osmolality 480 mOsm/kg) does not respond adequately to fluid restriction alone. His physician considers adding a pharmacological agent. Tolvaptan is selected. Which of the following best describes the mechanism and critical safety limitation of tolvaptan in this patient?

A) Tolvaptan antagonizes V1a vasopressin receptors on vascular smooth muscle, causing vasodilation and reducing afterload in heart failure while simultaneously correcting hyponatremia through renal water excretion
B) Tolvaptan is a loop diuretic that increases free water excretion by blocking the Na-K-2Cl cotransporter, producing aquaresis without affecting sodium excretion
C) Tolvaptan is contraindicated in all forms of hyponatremia because its aquaretic effect inevitably causes overcorrection and osmotic demyelination syndrome within the first 24 hours of use
D) Tolvaptan selectively antagonizes V2 vasopressin receptors in the collecting duct, blocking ADH-mediated AQP2 insertion and producing electrolyte-free water excretion (aquaresis); it must not be used in hypovolemic hyponatremia and must be initiated only in monitored inpatient settings due to rapid correction risk
E) Tolvaptan stimulates V2 vasopressin receptors in the collecting duct, increasing AQP2 expression and thereby concentrating the urine to reduce free water loss and raise serum sodium

ANSWER: D

Rationale:

Tolvaptan is a selective V2 vasopressin receptor antagonist (vaptan). In the collecting duct, V2 receptor activation by ADH normally triggers cAMP-mediated insertion of AQP2 (aquaporin-2) water channels into the apical membrane, allowing water reabsorption. Tolvaptan blocks this V2 receptor, preventing AQP2 insertion and producing aquaresis — the excretion of electrolyte-free water without significant sodium loss. This selectively raises serum sodium in hyponatremia states driven by excess ADH, including SIADH and certain hypervolemic states. Critical safety limitations: (1) tolvaptan is contraindicated in hypovolemic hyponatremia, where free water excretion would worsen volume depletion; (2) it must be initiated only in monitored inpatient settings because the rate of sodium correction can be unpredictable and rapid, risking ODS; (3) patients should not be on strict fluid restriction simultaneously, as this can accelerate overcorrection.

Option A: Option A is incorrect: tolvaptan is V2-selective, not V1a; V1a antagonism on vascular smooth muscle is the mechanism of conivaptan (which is V1a/V2 non-selective), not tolvaptan.
Option B: Option B is incorrect: tolvaptan is not a loop diuretic and does not act on the Na-K-2Cl cotransporter; it acts on V2 receptors in the collecting duct.
Option C: Option C is incorrect: tolvaptan is not contraindicated in all forms of hyponatremia — it is specifically contraindicated in hypovolemic hyponatremia; it is indicated for euvolemic and hypervolemic hyponatremia with appropriate monitoring.
Option E: Option E is incorrect: tolvaptan antagonizes (blocks) V2 receptors — it does not stimulate them; stimulation of V2 receptors is the mechanism of desmopressin (DDAVP), which would worsen hyponatremia.

13. A 52-year-old man with combined metabolic and respiratory acidosis (pH 6.98, PaCO₂ 68 mmHg, HCO₃⁻ 16 mEq/L) from severe pneumonia and acute respiratory failure is intubated and mechanically ventilated. His serum sodium is 148 mEq/L and he has oliguric acute kidney injury. The intensivist considers an alkalinizing agent but notes that standard IV sodium bicarbonate is problematic in this patient. Tromethamine (THAM) is selected. Which of the following best describes why THAM is preferred over sodium bicarbonate in this specific clinical scenario, and what critical limitation constrains its use?

A) THAM accepts protons directly via its amino group without generating CO₂, avoiding the paradoxical worsening of hypercapnia that bicarbonate buffering would cause in a patient with impaired CO₂ elimination; however, THAM requires intact renal function for its own elimination, making this patient's oliguric AKI a significant contraindication that must be weighed against the need for CO₂-neutral buffering
B) THAM is preferred because it contains no sodium, eliminating the risk of hypernatremia from sodium loading, and it can be administered safely at full doses in patients with acute kidney injury because it is eliminated entirely by hepatic metabolism rather than renal excretion
C) THAM is preferred because it directly inhibits carbonic anhydrase in the proximal convoluted tubule, promoting urinary bicarbonate excretion and correcting metabolic acidosis without generating CO₂ or adding a sodium load
D) THAM is preferred because it stimulates renal H⁺-ATPase activity in the collecting duct, enhancing net acid excretion and regenerating bicarbonate more rapidly than sodium bicarbonate can provide it exogenously
E) THAM is preferred because it has a significantly faster onset of action than sodium bicarbonate — raising systemic pH within 2 minutes compared with 15–30 minutes for bicarbonate — making it the agent of choice whenever rapid pH correction is needed regardless of renal function

ANSWER: A

Rationale:

Tromethamine (THAM) is an aminoalcohol buffer that accepts protons (H⁺) directly via its amino group, producing a protonated THAM molecule without generating carbon dioxide. This CO₂-neutral mechanism is the critical advantage over sodium bicarbonate in this patient: the bicarbonate buffering reaction (HCO₃⁻ + H⁺ → H₂CO₃ → CO₂ + H₂O) generates CO₂, which would worsen hypercapnia in a patient whose CO₂ elimination is already impaired (PaCO₂ 68 mmHg despite mechanical ventilation). The sodium loading of bicarbonate is also problematic given the patient's hypernatremia (Na 148 mEq/L). However, a critical limitation is that THAM requires intact renal function for its own elimination; this patient's oliguric AKI substantially limits THAM's usability — THAM can accumulate and cause hypoglycemia and respiratory depression. The scenario illustrates a genuine clinical dilemma where both agents have significant contraindications.

Option B: Option B is incorrect: while THAM contains no sodium (an advantage in this hypernatremic patient), THAM is eliminated renally, not hepatically — oliguric AKI is a contraindication to THAM, not a reason it can be given safely at full doses.
Option C: Option C is incorrect: THAM does not inhibit carbonic anhydrase; carbonic anhydrase inhibition causing urinary bicarbonate wasting is the mechanism of acetazolamide, not THAM.
Option D: Option D is incorrect: THAM does not stimulate renal H⁺-ATPase activity in the collecting duct; its mechanism is direct proton buffering in the systemic circulation, not enhanced renal acid excretion.
Option E: Option E is incorrect: THAM does not have a faster onset than sodium bicarbonate; the preference for THAM is based on its CO₂-neutral buffering mechanism in the setting of combined acidosis with impaired CO₂ clearance, not on superior speed of pH correction.

14. A 38-year-old woman with bipolar disorder has been on lithium therapy for 6 years. She presents with polyuria (estimated 10 liters/day) and polydipsia. Serum sodium is 148 mEq/L, serum osmolality 305 mOsm/kg, and urine osmolality 85 mOsm/kg. Water deprivation testing followed by desmopressin administration shows no increase in urine osmolality. Which of the following best explains the mechanism of lithium-induced nephrogenic diabetes insipidus (NDI) and the first-line pharmacological treatment?

A) Lithium inhibits aldosterone binding to the mineralocorticoid receptor in collecting duct principal cells, reducing ENaC expression and preventing sodium-driven water reabsorption; fludrocortisone is the first-line treatment to restore mineralocorticoid activity
B) Lithium blocks V2 vasopressin receptors on collecting duct principal cells, preventing ADH-mediated cAMP generation; desmopressin at supraphysiological doses overcomes this competitive antagonism and is the first-line treatment
C) Lithium enters collecting duct principal cells via ENaC (epithelial sodium channel), accumulates intracellularly, and inhibits adenylate cyclase-mediated cAMP generation, preventing vasopressin-stimulated AQP2 insertion; amiloride is the first-line treatment because it blocks ENaC and reduces lithium accumulation in collecting duct cells
D) Lithium activates aquaporin-2 degradation pathways in the collecting duct by stimulating ubiquitin-mediated proteasomal processing of AQP2, reducing channel protein levels; loop diuretics are the first-line treatment to paradoxically increase proximal tubular water reabsorption
E) Lithium causes hypokalemia by blocking the ROMK channel in the collecting duct, which secondarily reduces AQP2 trafficking; potassium supplementation restores AQP2 function and resolves the NDI without other pharmacological intervention

ANSWER: C

Rationale:

Lithium enters collecting duct principal cells via the epithelial sodium channel (ENaC), for which it is a substrate. Once intracellular, lithium inhibits adenylate cyclase, preventing the generation of cAMP in response to vasopressin (ADH) binding at the V2 receptor. Without cAMP, protein kinase A cannot phosphorylate AQP2 (aquaporin-2) vesicles for insertion into the apical membrane, and collecting duct water permeability remains low — producing nephrogenic diabetes insipidus (NDI) with inability to concentrate urine regardless of ADH level. The response to exogenous desmopressin (as in this patient's water deprivation test) is absent because the defect is post-receptor (intracellular). Amiloride is the first-line treatment: it blocks ENaC, reducing lithium entry into principal cells, thereby attenuating the adenylate cyclase inhibition and partially restoring AQP2 responsiveness. Thiazide diuretics can also reduce polyuria via volume contraction-driven proximal sodium reabsorption but increase serum lithium levels.

Option A: Option A is incorrect: lithium does not act via the mineralocorticoid receptor or aldosterone pathway; fludrocortisone has no role in lithium-induced NDI.
Option B: Option B is incorrect: lithium does not block V2 receptors competitively; its action is intracellular (inhibition of adenylate cyclase), which is why supraphysiological desmopressin doses cannot overcome the defect.
Option D: Option D is incorrect: while AQP2 downregulation is the end result, lithium does not act via ubiquitin-mediated proteasomal degradation pathways; loop diuretics are not first-line therapy for lithium-induced NDI (and would worsen volume depletion).
Option E: Option E is incorrect: lithium-induced NDI is not caused by ROMK channel blockade or secondary hypokalemia; ROMK is a potassium channel in the thick ascending limb and collecting duct regulated by aldosterone, not lithium.

15. A 44-year-old man receiving conventional amphotericin B deoxycholate for invasive aspergillosis develops serum potassium of 2.6 mEq/L, serum magnesium of 0.9 mg/dL, and a urine pH that cannot fall below 5.5 despite systemic acidemia. Which of the following best explains the mechanism responsible for this constellation of findings?

A) Amphotericin B inhibits Na/K-ATPase in the thick ascending limb, reducing the lumen-positive potential that drives passive potassium and magnesium reabsorption, causing urinary wasting of both cations
B) Amphotericin B chelates ionized calcium and magnesium directly in the tubular lumen, reducing their reabsorption and causing hypomagnesemia and hypocalcemia; the RTA pattern results from calcium crystal deposition in the distal tubule
C) Amphotericin B inhibits the H⁺/K⁺-ATPase in collecting duct alpha-intercalated cells, preventing both hydrogen ion secretion and potassium reabsorption simultaneously, causing RTA and hypokalemia without tubular membrane disruption
D) Amphotericin B inserts into mammalian renal tubular cell membranes at cholesterol-rich sites in the distal tubule and collecting duct, forming pores that increase membrane permeability to potassium and hydrogen ions, causing potassium wasting, impaired H⁺ secretion producing a type 1 RTA pattern, and hypomagnesemia from reduced magnesium reabsorption
E) Amphotericin B activates the mineralocorticoid receptor in the collecting duct, driving excessive potassium and hydrogen ion secretion; the hypomagnesemia results from secondary aldosteronism induced by the drug's vasoconstrictive effects on the afferent arteriole

ANSWER: D

Rationale:

Conventional amphotericin B deoxycholate inserts into ergosterol-rich fungal cell membranes to exert its antifungal effect, but at renal tubular concentrations it also inserts into mammalian tubular cell membranes at cholesterol-rich sites, particularly in the distal tubule and collecting duct. This membrane pore formation increases permeability to potassium and hydrogen ions: potassium leaks out through the pores, causing urinary potassium wasting and hypokalemia; hydrogen ion secretion by intercalated cells is impaired because the created pores dissipate the proton gradient needed for net H⁺ secretion, producing a type 1 (distal) RTA pattern — urine pH cannot fall below 5.5. Hypomagnesemia results from reduced magnesium reabsorption in the TAL and distal tubule due to the membrane disruption. Lipid formulations substantially reduce tubular toxicity by limiting free amphotericin B exposure.

Option A: Option A is incorrect: amphotericin B does not inhibit Na/K-ATPase; the lumen-positive potential in the TAL is maintained by Na-K-2Cl cotransport and ROMK — disruption of this is the mechanism of loop diuretics, not amphotericin.
Option B: Option B is incorrect: direct tubular lumen chelation of calcium and magnesium is the mechanism of foscarnet, not amphotericin B.
Option C: Option C is incorrect: amphotericin B does not selectively inhibit H⁺/K⁺-ATPase; its mechanism is non-selective membrane pore formation, not enzymatic inhibition of a specific transporter.
Option E: Option E is incorrect: amphotericin B does not activate mineralocorticoid receptors; its tubular toxicity is a direct consequence of membrane pore formation, not secondary aldosteronism.

16. A 52-year-old woman with ovarian cancer received six cycles of cisplatin-based chemotherapy completing 3 months ago. Her renal function has normalized (creatinine 0.9 mg/dL), but she continues to have serum magnesium of 0.7 mg/dL requiring weekly IV replacement. She also has persistent serum potassium of 3.1 mEq/L despite aggressive oral potassium supplementation. Which of the following best explains why her hypokalemia is refractory to potassium replacement alone?

A) Cisplatin permanently inhibits aldosterone synthesis in the adrenal cortex, causing ongoing potassium wasting through reduced mineralocorticoid-driven sodium-potassium exchange in the collecting duct
B) Cisplatin damages TRPM6 channels in the distal convoluted tubule, causing persistent urinary magnesium wasting; hypomagnesemia prevents intracellular blockade of ROMK from the cytoplasmic side, causing constitutive renal potassium secretion that cannot be corrected until magnesium is repleted
C) Cisplatin causes permanent type 4 RTA by destroying juxtaglomerular cells, eliminating renin production and creating a hyporenin-hypoaldosteronism state that drives potassium retention, not wasting
D) The refractory hypokalemia reflects inadequate oral supplementation dose rather than a mechanistic barrier; increasing potassium chloride to 160 mEq/day will restore normokalemia within 48 hours regardless of magnesium status
E) Cisplatin-induced SIADH causes dilutional hypokalemia by expanding total body water; correcting the hyponatremia with fluid restriction will simultaneously normalize serum potassium without magnesium replacement

ANSWER: B

Rationale:

Cisplatin damages the TRPM6 (transient receptor potential melastatin 6) channel, the primary apical magnesium entry channel in the distal convoluted tubule (DCT), causing persistent urinary magnesium wasting that can last months to years even after renal function normalizes — as demonstrated in this patient. The refractory hypokalemia results from the magnesium-potassium interdependence: magnesium is required to block ROMK (renal outer medullary potassium channel) from the intracellular (cytoplasmic) side. Without adequate intracellular magnesium, ROMK remains constitutively open and continuously secretes potassium into the collecting duct lumen, regardless of how much potassium is supplemented orally or IV. Potassium replacement will be ineffective until hypomagnesemia is corrected aggressively (IV magnesium sulfate). This mechanism is clinically critical — any unexplained refractory hypokalemia in a patient who has received cisplatin, amphotericin B, aminoglycosides, or CNIs mandates checking and aggressively replacing magnesium.

Option A: Option A is incorrect: cisplatin does not permanently inhibit aldosterone synthesis in the adrenal cortex; its primary renal toxicity is tubular, targeting TRPM6 in the DCT and causing proximal tubular injury.
Option C: Option C is incorrect: cisplatin does not destroy juxtaglomerular cells or cause type 4 RTA with potassium retention; the electrolyte defects from cisplatin are wasting disorders (hypomagnesemia, hypokalemia), not retention.
Option D: Option D is incorrect: the hypokalemia is mechanistically refractory because ROMK-mediated potassium secretion will continue as long as hypomagnesemia persists; oral supplementation dose escalation alone cannot overcome constitutively open ROMK in the absence of magnesium.
Option E: Option E is incorrect: cisplatin does not cause SIADH as a persistent post-chemotherapy effect; dilutional hypokalemia from SIADH is not the mechanism of the persistent hypokalemia described, and fluid restriction would not address the TRPM6/ROMK-mediated potassium wasting.

17. A 55-year-old man with diabetic ketoacidosis (pH 7.05, HCO₃⁻ 6 mEq/L, PaCO₂ 18 mmHg by compensatory hyperventilation) is being treated with insulin and IV fluids. His team considers IV sodium bicarbonate to rapidly raise his pH. Which of the following best explains the mechanism of the paradoxical central nervous system (CNS) worsening that can occur despite rising blood pH after bicarbonate infusion?

A) Bicarbonate infusion causes acute hypernatremia, which directly increases CSF osmolality and drives water into neuronal cells, causing cytotoxic edema that worsens mental status independent of acid-base changes
B) The sodium load of bicarbonate formulations activates RAAS, causing aldosterone-mediated potassium excretion and hypokalemia, which depolarizes neuronal membranes and causes CNS excitability
C) Bicarbonate infusion stimulates insulin release from the pancreas, causing acute hypoglycemia that worsens the altered mental status already present in DKA
D) Carbon dioxide (CO₂), generated by the bicarbonate buffering reaction, diffuses rapidly across the blood-brain barrier while bicarbonate crosses slowly; this transiently worsens CSF acidosis even as arterial pH rises — producing paradoxical CNS acidosis despite improving systemic pH
E) Bicarbonate infusion suppresses the compensatory hyperventilation reflex, raising PaCO₂ acutely and worsening the respiratory component of the combined acidosis before the metabolic correction takes effect

ANSWER: D

Rationale:

The buffering reaction of sodium bicarbonate is: HCO₃⁻ + H⁺ → H₂CO₃ → CO₂ + H₂O. The CO₂ generated by this reaction diffuses rapidly across the blood-brain barrier (BBB) — CO₂ is lipophilic and crosses freely. Bicarbonate, by contrast, crosses the BBB slowly and poorly. Within the CSF, CO₂ is hydrated back to H₂CO₃ and then dissociates to H⁺ and HCO₃⁻, acutely lowering CSF pH even while systemic (arterial) pH is rising in response to the bicarbonate infusion. This is paradoxical CNS acidosis — the brain experiences worsening acidosis at the very moment the blood is being alkalinized. In patients with DKA, whose compensatory hyperventilation keeps PaCO₂ very low, the absolute amount of CO₂ generated may overwhelm CNS buffering capacity. This mechanism, along with hypernatremia and volume overload from the sodium load, explains why IV bicarbonate is not routinely recommended in DKA or lactic acidosis.

Option A: Option A is incorrect: while hypernatremia from sodium loading is a real complication of bicarbonate infusion, cytotoxic edema from CSF osmolality change is not the mechanism of paradoxical CNS acidosis; the mechanism is CO₂ diffusion across the BBB causing CSF pH to fall.
Option B: Option B is incorrect: RAAS activation and aldosterone-mediated hypokalemia do not cause paradoxical CNS worsening in the acute timeframe described; this is not the mechanism of paradoxical CNS acidosis.
Option C: Option C is incorrect: bicarbonate infusion does not stimulate insulin release from the pancreas; hypoglycemia prevention in this scenario is relevant to insulin therapy, not bicarbonate.
Option E: Option E is incorrect: while suppression of hyperventilation is a theoretical concern with bicarbonate (as chemoreceptors respond to rising pH), this effect is modest and is not the primary mechanism of paradoxical CNS acidosis; the CO₂ diffusion mechanism is the established explanation.

18. A 61-year-old man receiving amphotericin B for candidemia develops serum potassium of 2.8 mEq/L and serum magnesium of 0.8 mg/dL. Despite receiving 120 mEq of IV potassium chloride over 12 hours, his serum potassium rises only to 3.0 mEq/L. Which of the following best explains the next priority in managing his refractory hypokalemia?

A) Aggressively replace magnesium with IV magnesium sulfate before expecting potassium levels to normalize, because magnesium is required to block ROMK from the intracellular side, and without it ROMK remains constitutively open causing ongoing renal potassium secretion regardless of how much potassium is supplemented
B) Increase the potassium chloride infusion rate to 20 mEq/hour to overcome the ongoing urinary losses, as higher infusion rates will saturate the tubular secretion mechanism and allow potassium to accumulate
C) Switch from IV potassium chloride to oral potassium gluconate, as the gluconate formulation has superior bioavailability and is more efficiently retained in the intracellular compartment in the setting of drug-induced tubular toxicity
D) Add fludrocortisone to stimulate ENaC-mediated sodium reabsorption, which will secondarily reduce ROMK-mediated potassium secretion in the collecting duct through volume expansion-mediated suppression of RAAS
E) Discontinue amphotericin B immediately and switch to a topical antifungal agent, as the only effective management of amphotericin-induced hypokalemia is drug cessation, with no role for electrolyte replacement until the drug is stopped

ANSWER: A

Rationale:

In the setting of amphotericin B-induced hypomagnesemia, refractory hypokalemia is a predictable and well-recognized clinical trap. Magnesium is required to block the renal outer medullary potassium channel (ROMK) from the intracellular (cytoplasmic) side. ROMK is the principal potassium secretory channel in the collecting duct and thick ascending limb. When intracellular magnesium is depleted, this intracellular blockade is lost, and ROMK remains constitutively open — continuously secreting potassium into the tubular lumen regardless of how much potassium is replaced intravenously. The kidney cannot retain infused potassium because it is immediately secreted through unblocked ROMK channels. The management priority is aggressive IV magnesium sulfate replacement (typically 1–2 g IV over 30–60 min, repeated as needed) before expecting potassium levels to normalize. Once magnesium is repleted and ROMK is re-blocked, potassium replacement becomes effective.

Option B: Option B is incorrect: increasing the infusion rate will not overcome the ROMK-mediated loss while hypomagnesemia persists; the potassium will continue to be excreted and the approach does not address the root mechanism.
Option C: Option C is incorrect: the route or formulation of potassium supplementation is not the limiting factor; the mechanism driving refractory hypokalemia is ROMK channel constitutive opening due to magnesium deficiency, not bioavailability of the potassium formulation.
Option D: Option D is incorrect: fludrocortisone (a mineralocorticoid) would actually increase aldosterone-mediated ENaC activity and worsen potassium secretion; it is not a treatment for drug-induced hypokalemia with concurrent hypomagnesemia.
Option E: Option E is incorrect: while switching to a lipid formulation of amphotericin or an alternative antifungal is appropriate when clinically feasible, continuing to withhold potassium and magnesium replacement is not appropriate; electrolyte replacement proceeds in parallel with any drug modification decisions.

19. A 34-year-old man with HIV and hepatitis B coinfection has been on tenofovir disoproxil fumarate (TDF)-containing antiretroviral therapy for 4 years. His creatinine is 1.3 mg/dL (baseline 0.8 mg/dL). Urinalysis shows glycosuria with a fasting glucose of 92 mg/dL, phosphaturia, and aminoaciduria. His serum phosphate is 1.8 mg/dL and venous HCO₃⁻ is 18 mEq/L. Which of the following best explains the mechanism of these findings?

A) TDF causes type 1 (distal) RTA by forming pores in collecting duct principal cell membranes, impairing H⁺ secretion and causing an inability to lower urine pH below 5.5, with secondary urinary phosphate and glucose wasting
B) TDF causes hyperkalemia and type 4 RTA by inhibiting ENaC in the collecting duct, reducing the electronegativity of the tubular lumen that drives potassium secretion and bicarbonate reabsorption
C) TDF accumulates in proximal convoluted tubule mitochondria via OAT1-mediated uptake and inhibits mitochondrial DNA polymerase gamma, causing mitochondrial dysfunction and a full Fanconi syndrome characterized by phosphaturia, glycosuria despite normoglycemia, aminoaciduria, and a type 2 proximal RTA pattern
D) TDF blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal convoluted tubule, producing glycosuria; the phosphaturia and aminoaciduria result from osmotic tubular injury caused by the high glucose concentration in the tubular lumen
E) TDF inhibits Na/K-ATPase throughout the nephron, disrupting the electrochemical gradient required for secondary active transport of glucose, phosphate, and amino acids in the proximal tubule, causing pan-proximal wasting

ANSWER: C

Rationale:

TDF (tenofovir disoproxil fumarate) is a nucleotide reverse transcriptase inhibitor that is actively secreted into proximal convoluted tubule (PCT) cells via the organic anion transporter OAT1. Within PCT mitochondria, TDF's active metabolite (tenofovir diphosphate) inhibits mitochondrial DNA polymerase gamma, the enzyme responsible for mitochondrial DNA replication. This causes mitochondrial dysfunction, impairing the energy-dependent active transport processes in the PCT that reabsorb glucose, phosphate, amino acids, uric acid, and bicarbonate. The result is Fanconi syndrome — simultaneous proximal tubular dysfunction causing glycosuria (despite normoglycemia), phosphaturia, aminoaciduria, and a type 2 proximal RTA pattern (urinary bicarbonate wasting). Switching from TDF to tenofovir alafenamide fumarate (TAF), a prodrug that achieves effective intracellular concentrations at 90% lower plasma equivalent concentrations, substantially reduces renal and bone toxicity.

Option A: Option A is incorrect: type 1 (distal) RTA with pore formation in collecting duct cells is the mechanism of amphotericin B, not TDF; TDF targets the proximal tubule mitochondria.
Option B: Option B is incorrect: type 4 RTA from ENaC inhibition is the mechanism of amiloride and, secondarily, of calcineurin inhibitors; TDF's nephrotoxicity causes proximal tubule dysfunction (Fanconi syndrome), not collecting duct ENaC inhibition.
Option D: Option D is incorrect: SGLT2 inhibition in the PCT is the mechanism of the SGLT2 inhibitor drug class (empagliflozin, dapagliflozin, canagliflozin), not TDF; TDF does not target glucose cotransporters and does not cause osmotic tubular injury from glycosuria.
Option E: Option E is incorrect: TDF does not inhibit Na/K-ATPase; its mechanism is specific to mitochondrial DNA polymerase gamma inhibition, causing organelle dysfunction rather than direct transporter inhibition.

20. A 78-year-old woman with atrial fibrillation is maintained on digoxin 0.125 mg daily. She presents with acute hyperkalemia (K 6.4 mEq/L) and ECG changes. The team moves to administer calcium gluconate as the first step of the acute hyperkalemia protocol. The attending physician raises a specific concern about this patient. Which of the following best identifies the pharmacological basis for this concern and the appropriate clinical response?

A) Calcium gluconate is absolutely contraindicated in patients on digoxin and must never be administered regardless of the severity of hyperkalemia; hemodialysis is the only safe first-line intervention in digoxin-treated patients with hyperkalemia
B) Calcium gluconate should not be given in patients on digoxin because calcium directly competes with digoxin for binding sites on the alpha subunit of Na/K-ATPase, displacing digoxin and paradoxically worsening hyperkalemia by unblocking the pump
C) Calcium gluconate is safe in digoxin-treated patients because digoxin acts only on Na/K-ATPase and calcium acts only on membrane threshold potential; these mechanisms do not interact and no special precautions are needed
D) Digoxin toxicity is uniquely triggered by hypocalcemia rather than hypercalcemia; calcium gluconate therefore protects against digoxin-induced arrhythmias and should be given at double the standard dose in this clinical scenario to provide extra margin
E) Hypercalcemia potentiates digoxin toxicity through additive intracellular calcium loading in cardiac myocytes — digoxin inhibits Na/K-ATPase raising intracellular Na⁺, which reduces NCX-mediated calcium efflux and raises intracellular Ca²⁺; exogenous calcium compounds this effect, increasing arrhythmia risk — therefore calcium gluconate should be given cautiously as a slow infusion rather than a bolus, with close monitoring for digoxin toxicity signs; it is not absolutely contraindicated in life-threatening hyperkalemia

ANSWER: E

Rationale:

The pharmacological concern is that hypercalcemia potentiates digoxin toxicity through a well-characterized mechanism. Digoxin inhibits Na/K-ATPase, causing intracellular sodium accumulation. The elevated intracellular Na⁺ reduces the driving force for the sodium-calcium exchanger (NCX), which normally extrudes calcium from the cell — NCX operates by exchanging 3 Na⁺ in for 1 Ca²⁺ out. Reduced NCX activity causes intracellular calcium to rise, producing both the therapeutic positive inotropy and the proarrhythmic triggered activity (delayed afterdepolarizations) of digoxin toxicity. Exogenous calcium from calcium gluconate raises extracellular calcium and secondarily raises intracellular calcium, adding to the already-elevated intracellular calcium load from digoxin's effect. This potentiates triggered ventricular arrhythmias. However, in life-threatening hyperkalemia with imminent cardiac arrest, withholding calcium gluconate would be more dangerous than the digoxin interaction. The clinically accepted approach is slow IV infusion rather than bolus administration, with continuous monitoring.

Option A: Option A is incorrect: calcium gluconate is not absolutely contraindicated in digoxin-treated patients; withholding it in severe hyperkalemia with ECG changes risks immediate ventricular fibrillation, which is more dangerous than the digoxin-calcium interaction when the agent is given cautiously.
Option B: Option B is incorrect: calcium does not compete with digoxin for Na/K-ATPase binding sites; digoxin binds to a specific extracellular domain of the alpha subunit, while calcium's membrane-stabilizing effect is through surface charge neutralization of the lipid bilayer — these are distinct mechanisms with no direct competitive interaction.
Option C: Option C is incorrect: stating that calcium and digoxin have no pharmacodynamic interaction is factually wrong; the NCX-mediated intracellular calcium loading interaction is a well-established mechanism that mandates cautious administration.
Option D: Option D is incorrect: the clinical teaching is precisely the opposite — hypercalcemia (not hypocalcemia) potentiates digoxin toxicity; hypokalemia (not hypocalcemia) is the electrolyte disturbance that most sensitizes the heart to digoxin toxicity, and calcium gluconate administration should not be doubled in digoxin-treated patients.

21. A 69-year-old man with CKD stage 4 and serum potassium of 6.2 mEq/L presents to the emergency department. He has peaked T waves on ECG. After calcium gluconate and insulin-dextrose are administered, the team discusses oral potassium binders. A clinician notes that this patient has a second acute problem requiring hospitalization and that rapid-onset potassium lowering in the next few hours is desirable. Which of the following agents is most appropriate to achieve potassium lowering with onset within approximately 1 hour?

A) Patiromer (Veltassa) 8.4 g orally, because as a calcium-zirconium polymer it binds potassium throughout the entire gastrointestinal tract and begins working within 30 minutes of administration
B) Sodium zirconium cyclosilicate (SZC; Lokelma) 10 g orally three times daily for the first 24 hours, because SZC has an onset of approximately 1 hour and regulatory approval for acute hyperkalemia management
C) Sodium polystyrene sulfonate (Kayexalate) 30 g rectally, because rectal administration bypasses hepatic first-pass metabolism and achieves the most rapid onset of any potassium binder currently available
D) Patiromer 25.2 g orally as a loading dose, because the higher dose compensates for the slower onset and achieves equivalent 1-hour potassium lowering compared with SZC
E) Either patiromer or SZC may be used interchangeably for acute hyperkalemia as both have FDA approval for acute management and equivalent 1-hour onset profiles

ANSWER: B

Rationale:

Sodium zirconium cyclosilicate (SZC; Lokelma) is the correct choice for this patient. SZC is a highly selective potassium-zirconium crystal that traps potassium throughout the gastrointestinal tract via ion exchange, with an onset of approximately 1 hour. It has regulatory approval for both acute and chronic hyperkalemia management. The standard acute dosing is 10 g orally three times daily for the first 24 hours (correction phase), followed by 10 g once daily for maintenance. Patiromer (Veltassa), by contrast, has an onset of 4–24 hours — too slow for the acute requirement described. For a patient in whom rapid potassium lowering over the next few hours is clinically desired, SZC is the appropriate selection between the two modern binders.

Option A: Option A is incorrect: patiromer is a calcium-zirconium polymer that acts in the colon (not throughout the entire GI tract — that description applies to SZC); its onset is 4–24 hours, making it inappropriate for acute use.
Option C: Option C is incorrect: sodium polystyrene sulfonate (Kayexalate) is no longer preferred due to reports of intestinal necrosis and variable efficacy; it does not have the fastest onset profile among currently available agents, and rectal administration does not achieve a 1-hour onset.
Option D: Option D is incorrect: increasing the patiromer dose does not compensate for its fundamental pharmacokinetic limitation — its onset is determined by colonic transit and binding kinetics, not dose size; there is no evidence that a loading dose achieves 1-hour efficacy.
Option E: Option E is incorrect: the two agents are not interchangeable for acute management — patiromer is approved for chronic management only, while SZC has dual acute and chronic approval.

22. A 49-year-old woman with primary hyperaldosteronism (confirmed by elevated aldosterone-to-renin ratio and adrenal CT showing a left adrenal adenoma) has serum bicarbonate of 31 mEq/L, pH 7.47, serum potassium 2.9 mEq/L, and urine chloride of 42 mEq/L. Her physician correctly identifies chloride-resistant metabolic alkalosis. The team considers isotonic saline infusion. Which of the following best explains why saline will not correct this patient's metabolic alkalosis?

A) Saline is ineffective because the patient's elevated urine chloride indicates that chloride stores are already replete; the limiting factor is excessive bicarbonate generation from the proximal tubule that isotonic saline cannot suppress
B) Saline is ineffective because it is hypotonic relative to this patient's extracellular fluid, causing dilutional worsening of hypokalemia that perpetuates the alkalosis by increasing collecting duct H⁺ secretion
C) Saline is ineffective because the urine chloride above 20 mEq/L indicates that loop diuretics — not saline — are the appropriate first-line treatment to correct the chloride excess by increasing urinary chloride excretion and restoring acid-base balance
D) Saline is ineffective in this patient because the autonomous aldosterone hypersecretion from the adrenal adenoma continuously drives collecting duct sodium reabsorption via ENaC, which sustains hydrogen ion secretion by alpha-intercalated cells and potassium secretion via ROMK regardless of volume status; saline expands volume but cannot suppress autonomous aldosterone production, so the collecting duct H⁺ secretion and alkalosis maintenance continue unabated — treatment must address the aldosterone excess directly with adrenalectomy or mineralocorticoid receptor antagonists
E) Saline is ineffective because it activates the renin-angiotensin system through baroreceptor-mediated renin release, worsening aldosterone secretion from the adenoma and perpetuating the alkalosis despite volume expansion

ANSWER: D

Rationale:

In chloride-resistant metabolic alkalosis, the urine chloride is above 20 mEq/L (this patient: 42 mEq/L), indicating that ongoing aldosterone-mediated pathology — not chloride or volume depletion — drives the alkalosis. In primary hyperaldosteronism, the adrenal adenoma secretes aldosterone autonomously, independent of volume or renin status. Aldosterone stimulates ENaC in collecting duct principal cells, creating luminal electronegativity that drives potassium secretion via ROMK and hydrogen ion secretion via H⁺-ATPase in alpha-intercalated cells. The continuous H⁺ secretion regenerates bicarbonate, maintaining the metabolic alkalosis, while the potassium secretion causes hypokalemia that further stimulates H⁺ secretion (cells secrete H⁺ to retain K⁺). Saline infusion expands extracellular volume but has no mechanism to suppress an autonomous aldosterone-secreting adenoma; the collecting duct processes continue unaffected. Definitive treatment is adrenalectomy for a unilateral adenoma, or medical management with spironolactone or eplerenone (mineralocorticoid receptor antagonists) while awaiting or declining surgery.

Option A: Option A is incorrect: while the elevated urine chloride indicates chloride stores are not depleted, the mechanism of saline failure is not excessive proximal bicarbonate generation — it is the ongoing aldosterone-driven collecting duct H⁺ secretion that cannot be suppressed by volume repletion regardless of chloride status.
Option B: Option B is incorrect: isotonic saline is not hypotonic relative to extracellular fluid; it contains 154 mEq/L of both sodium and chloride (approximately isosmolar to plasma) and does not cause dilutional hypokalemia through a tonicity mechanism.
Option C: Option C is incorrect: loop diuretics increase urinary chloride excretion but would worsen volume depletion and hypokalemia, perpetuating rather than resolving aldosterone-driven metabolic alkalosis; they are not first-line treatment for chloride-resistant alkalosis from primary hyperaldosteronism.
Option E: Option E is incorrect: isotonic saline does not activate RAAS or stimulate renin release in a way that worsens an autonomous aldosterone-secreting adenoma; autonomous adenomas secrete aldosterone independently of renin stimulation and are unresponsive to the volume-mediated renin suppression that saline would ordinarily produce.